This study used NIH RePORTER data to characterize the clinical trial components of NIH career development (K) awards funded in fiscal years 2024–2025. The analysis focused on K01, K08, and K23 awards issued under funding opportunity announcements (FOAs) that were designated either CT Required or CT Optional. The primary objective was to describe the types and sizes of trials described in award abstracts, information that could inform policy decisions about NIH support for trial costs within K awards.
The authors identified 1,336 unique K awards funded under CT Required (n=1,051) or CT Optional (n=285) FOAs that had non-missing abstract text in NIH RePORTER. All data analyzed are available on reporter.nih.gov, which the authors cite as the source for award metadata and abstract text. The study excluded awards with missing abstract text; further inclusion or exclusion criteria beyond abstract availability were not reported in the source.
A deterministic, rule-based scheme was applied to free-text abstracts to assign each award to one of five mutually exclusive categories based on trial language in the abstract: 1) pilot/feasibility/proof-of-concept, 2) efficacy/effectiveness, 3) trial confirmed but type unclear, 4) other (including mechanistic, ancillary, or phase I/II studies), and 5) no trial-specific language identified. The source reports that sample sizes were assessed among abstracts that included an explicit, manually verified sample size. The exact classification rules and search terms used in the rule-based approach are described in the manuscript; specific rule lists are not reproduced here.
Across the full cohort of 1,336 awards, the largest category was pilot/feasibility/proof-of-concept studies, comprising 815 awards (61.0%). Efficacy/effectiveness trials were infrequently described, with 55 awards (4.1%) classified in that category. There were 204 awards (15.3%) with a confirmed trial where the trial type could not be further specified. The "other" category, which includes mechanistic, ancillary, and phase I/II studies, accounted for 41 awards (3.1%). Finally, 221 awards (16.5%) contained no trial-specific language in the abstract.
When limited to FOAs where a clinical trial was required (CT Required), pilot/feasibility/proof-of-concept studies were even more prominent: 730 of CT Required awards (69.5%) fell into that category. These distributions indicate that, within K award FOAs that encourage or require clinical trials, the predominant trial work described in abstracts is early-stage rather than large-scale definitive trials.
Among the 1,336 awards, 273 awards (20.4%) included an explicit, manually verified sample size in the abstract. For these awards the median reported sample size was 60 participants (interquartile range, 44–80). Most of the awards with reported sizes were small: 236 of the 273 with verified sample sizes (86.4%) planned to enroll ≤100 participants. These figures underscore that K award–linked trials described in abstracts are generally small in scale.
The study interprets these findings as evidence that trials associated with NIH K career development awards are predominantly small, early-stage investigations—primarily pilot, feasibility, or proof-of-concept work. The authors highlight a policy-relevant concern: NIH announced that, beginning in 2027, it will no longer support costs associated with clinical trials for K awards. Given the predominance of small, trainee-led trials documented here, the authors suggest that removing trial cost support could adversely affect the development of future clinical trialists by constraining opportunities for trainees to lead and learn from these early-stage studies.
The analysis is based on free-text abstract content in NIH RePORTER and on a rule-based classification, so findings depend on abstract wording and the classification approach. Only awards with non-missing abstracts were included; 20.4% of awards reported an explicit sample size in the abstract, meaning most abstracts did not include sample-size details. The source indicates that full data are available at reporter.nih.gov and that supplementary materials and code were provided with the manuscript. The authors reported no competing interests and stated that appropriate ethical and reporting guidelines were followed.
Among NIH K01, K08, and K23 awards issued under CT Required or CT Optional FOAs in FY2024–2025, the majority of awards described pilot/feasibility/proof-of-concept trials, and when sample sizes were reported these trials were typically small (median 60 participants; most ≤100). The authors argue that NIH’s policy change to stop supporting trial costs for K awards may risk reducing trainee-led trial experience and could have negative implications for the future clinical trialist workforce. For additional methodological details, rule definitions, or the complete dataset, consult the manuscript and the NIH RePORTER entries referenced in the source.